Giovanni Di Perri

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.

Savino Sciascia, Franco Aprà, Alessandra Baffa et al. · PubMed · 2020 · 327 citations

Veterinary Medicine, Infectious Diseases, Pharmacology +6

Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals

Sandro Vento, Lorenza Guella, F. Mirandola et al. · The Lancet · 1995 · 191 citations

Life Sciences, Immunology, Infectious Diseases +11

The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years

Giovanni Guaraldi, Andrea Malagoli, Andrea Calcagno et al. · BMC Geriatrics · 2018 · 178 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +17